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Purpose: Anaplastic large cell lymphoma (ALCL), a CD30+
T-cell non-Hodgkin's lymphoma, represents only 2 - 8% of
lymphoma overall. Information on the clinical findings of
primary systemic ALCL in Korea is limited. Our aims were
to report the clinical features and outcomes of primary
systemic ALCL. Patients and Methods: We retrospectively
reviewed the medical records of 36 adult patients diagnosed
with primary systemic ALCL at Asan Medical Center from
February 1995 through June 2006. Results: Of 36 patients, 29
were male. The median age was 39 years (range, 17 - 67
years), and 26 (72%) presented with Ann Arbor stages III and
IV. The most commonly involved extranodal sites were bone
(n= 7) and soft tissue (n = 6). Thirty-two of all patients (89%)
were treated with an anthracycline-based regimen including
cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP)
as induction chemotherapy; 16 (50%) achieved complete
remission (CR), and 13 (41%) achieved partial remission (PR).
Median overall survival (OS) and event-free survival (EFS)
were 49 and 17 months, respectively. Univariate analysis showed
that performance status (p = 0.035), international prognostic
index (IPI) (p = 0.025), and age-adjusted IPI (p = 0.034) were
significant prognostic factors for OS, whereas anaplastic
lymphoma kinase (ALK) expression did not affect OS (p =
0.483). Conclusion: Our retrospective analysis of Korean
primary systemic ALCL patients showed that median OS was
49 months and overall response to CHOP was 91%. Perfor-
mance, IPI, and age-adjusted IPI were predictors of OS,
whereas ALK expression did not have prognostic significance.
Key Words: Anaplastic large cell lymphoma, anaplastic
lymphoma kinase, CD 30, prognosis, International Prognostic
Index
INTRODUCTION
Anaplastic large cell lymphoma (ALCL) is a
CD30-positive neoplasm of T-cell or null-cell line-
age with characteristic clinicopathologic features,
and accounts for 2 - 8% of all lymphomas.
1 Two
subsets of systemic ALCL are currently recognized
in the World Health Organization (WHO) classifi-
cation scheme.
2 One subset expresses the oncogenic
protein anaplastic lymphoma kinase (ALK) as a
result of either the t(2;5)(p23;q35) translocation or
variant alk rearrangement that does not involve
npm. The second subset includes ALK-negative
(ALK ) tumors that are morphologically similar to
ALK-positive (ALK+) ALCL and also express CD30.
3-8
The major subgroups of primary ALCL also have
been distinguished by the WHO classification
2 as
(1) systemic ALCL, a heterogeneous subgroup
with a broad spectrum of morphology, immuno-
phenotype, and clinical characteristics; and (2)
cutaneous ALCL, a spectrum of cutaneous CD30+
lymphoproliferative disorders with a uniformly
good prognosis.
9 The treatment of primary
cutaneous ALCL is conservative, consisting of
resection, with or without irradiation or low-dose
methotrexate, which is used in multifocal disease
not amenable to localized therapy. In contrast,
primary systemic ALCL requires multiagent
chemotherapy.
10
Despite recent advances in the characterization
of ALCL, little is known regarding the clinical
characteristics of Korean adult patients with
primary systemic ALCL. We therefore analyzed
the clinical features and treatment outcomes of 36
adult patients with primary systemic ALCL in
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A survey of the medical records at Asan Medical
Center (Seoul, Korea) identified 65 patients who
met the WHO classification between February
1995 and June 2006.
2 We excluded (1) 6 patients
under 15 years of age, (2) 16 with primary
cutaneous ALCL, (3) 1 with secondary systemic
ALCL from Hodgkin's disease, (4) 2 who died
before receiving any induction therapy including
chemotherapy, radiation, and resection, (5) 4
whose medical records were insufficient to
determine their clinical features and outcomes.
Thus, our patient cohort consisted of 36 patients
with adult primary systemic ALCL.
Clinical data
The medical records of these 36 adult patients
with primary systemic ALCL were retrospectively
reviewed. Diagnoses were based on a combination
of routine histology, immunohistochemistry, cyto-
genetics, molecular genetics, and/or flow
cytometry. The morphology was reviewed in all
36 cases. The available cases were tested for CD3,
CD4, CD8, CD20, CD30, CD79a, ALK-1, UCHL-1,
and PAX-5 to exclude B-cell lineage. Immuno-
histochemical analysis of ALK expression was
performed on 4 m-thick paraffin sections taken μ
from paraffin blocks of tissue samples from 30
patients. The biopsies of the remaining 6 patients
were processed at outside institutions or obtained
too long ago, making their paraffin blocks unavail-
able. Using the standard avidin-biotin-peroxidase
technique, immunostaining with mouse mono-
clonal antibody to ALK (1 : 25; DAKO Diagnostics,
Glousrup, Denmark) was performed in the
automated immunostainer after heat-induced
antigen retrieval protocols (Ventana ES automated
immunohistochemistry stainer, Tucson, AZ, USA).
Hyperplastic tonsils and a known case of ALK+
ALCL were used as negative and positive
controls, respectively.
The clinical features evaluated for potential
prognostic importance were gender, age, Ann
Arbor stage, B symptoms, performance status,
type and number of extranodal sites, and serum
lactate dehydrogenase (LDH) level. Performance
status was assessed according to the Eastern
Cooperative Oncology Group (ECOG) scale.
Treatment and response evaluation
Thirty-five patients (97%) received induction
chemotherapy. One patient did not receive any
chemotherapy and radiotherapy after complete
surgical excision of localized cervical lympha-
denopathy and had been in continuous CR for 17
months. Of 35 patients treated with chemo-
therapy, 31 (89%) received CHOP regimen; 1
received CHOP regimen and cytarabine together;
1 received regimens that included cyclophospha-
mide, etoposide, vincristine, bleomycin, metho-
trexate, and prednisolone plus or minus
cytarabine (Vanderbilt);
11 1 patient received
vincristine, methotrexate, dexamethasone, ifosfa-
mide, etoposide, cytarabine; vincristine, metho-
trexate, dexamethasone, cyclophosphamide, and
doxorubicin in addition to intrathecal injection of
methotrexate, cytarabine, and hydrocortisone
(BNHL); and 1 received other regimens. Response
was assessed according to IWC criteria.
12
Statistical analysis
Overall survival (OS) was measured from
diagnosis to death from any cause, with surviving
patient follow up censored at the last contact date.
EFS was defined as the time from the first therapy
to the first occurrence of relapse, progression, or
death from any cause. Follow up of patients not
experiencing any of these events was censored at
their date of last contact. To compare the clinical
characteristics between ALK+ and ALK ALCL,
independent t test was used for age and
Chi-square test was used for the other factors. OS
and EFS distributions were calculated using
Kaplan and Meier methods. Survival curves were
compared by log-rank or Breslow test according
to the presence of cross line on the survival curve.
Tests for comparison were regarded as significant
if the p value was less than 0.05.Anaplastic Large Cell Lymphoma in Korea
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RESULTS
Patient demographic and clinical characteristics
The demographic and clinical characteristics of
the 36 patients are shown in Table 1. Of the 36
patients, 29 (81%) were male. The median age was
39 years (range, 17 - 67 years). Five patients (14%)
were classified as Ann Arbor stage I, 5 (14%) as
stage II, 11 (30%) as stage III, and 15 (42%) as
stage IV. Lymphadenopathy was present in 30
patients (83%) at diagnosis: intraabdominal and
retroperitoneal lymphadenopathy in 19 (63%), and
mediastinal lymphadenopathy in 11 (37%).
Splenomegaly was observed in 8 patients (22%).
Twenty-six patients (72%) presented with ex-
tranodal involvement and 15 (42%) showed
involvement at 2 or more extranodal sites. Six
patients (17%) were assessed as having primary
extranodal lymphoma without any nodal
involvement. Bone (n = 7, 19%) and soft tissue (n=
6, 17%) were the most frequently involved sites,
followed by the lung, pleura, muscle, bone
marrow, and liver (n = 5, each). Soft tissue sites
included mesenteric, peritoneal, and retroperi-
toneal soft tissue masses. Involvement of the
gastrointestinal system including the stomach (n =
2) and small bowel (n = 3) was observed in 5
patients (14%). Thirty-two patients (89%) were
scored as ECOG scale 1 or 2 and 4 (11%) as ECOG
scale 3 or 4. B symptoms occurred in 21 patients
(58%), and serum LDH was elevated in 25 (70%).
Twenty-two patients (61%) were classified as low
and low-intermediate IPI score and 14 (39%) as
high-intermediate and high IPI score. However, 24
patients (66%) were scored as high-intermediate
and high age-adjusted IPI.
Clinical characteristics according to ALK staining
ALK staining was performed again in 30
patients (83%) by a pathologist because the biopsy
specimens from 6 patients were unavailable. We
defined the cases, showing any nuclear or
cytoplasmic positivity, as ALK+ ALCL. Of these
30 patients, 13 (43%) were ALK+ and 17 (57%)
were ALK (Table 2). The median age of ALK+
patients (33 years; range, 19 - 49 years) was
significantly lower than that of ALK patients (43
years; range, 17 - 67 years) (p = 0.047) but male to
female ratio (5.5 vs. 3.3, p=0.469), percent of patients
with advanced stage (III, IV) disease (85 vs. 59%,
p = 0.130), and percent of patients with extranodal
involvement (77 vs. 76%) did not differ signifi-
cantly. Eight ALK+ patients (62%) and 11 ALK
(65%) were low and low-intermediate IPI (p=0.861),
and 4 and 7, respectively, were low and low-inter-
mediate age-adjusted IPI (p = 0.421). As a whole,
8 survived and 5 died out of 13 ALK+ patients
and 8 survived and 9 died out of 17 ALK patients.
Treatment results
Thirty-five patients (97%) were treated with
combination chemotherapy regimens. The overall
response rate was 91% with CR in 51% (n = 18)
and PR in 40% (n = 14). Thirty-two patients (89%)
received CHOP-based chemotherapy regimen.
The overall response rate of CHOP-based
chemotherapy regimen was 91% with CR in 50%
(n = 16) and PR in 41% (n = 13). Two progressive
disease (PD) and 1 unknown response were
noted. Eighteen of 35 patients (50%) who received
chemotherapy relapsed; 15 patients within 12
months of diagnosis, with the others showing
relapse after 32, 40, and 52 months, respectively.
In 7 patients, the relapse sites included previous
disease sites whereas in 5, recurrences were at
both previous and new sites and 4 relapsed only
at new sites. Relapse sites of the remaining 2
patients were not reported.
Seventeen of 18 relapsed patients received
second-line chemotherapy: 4 received cytarabine,
cisplatin, and dexamethasone (DHAP); 3 received
Vanderbilt;
11 3 received etoposide, methylpredni-
solone, cytarabine, and cisplatin (ESHAP); and 7
received other regimens including CDDP plus
taxol and T-LBL. It showed 2 CRs (12%); 3, PRs
(18%); 1, stable disease (SD) (6%); and 8, PDs
(47%), respectively, and the medical records of 3
patients were insufficient to assess the clinical
responses of second-line chemotherapy.
One patient who relapsed after first-line chemo-
therapy and 2 after second-line chemotherapy
were treated with high-dose chemotherapy,
followed by autologous peripheral blood stem cell
transplantation. One patient has remained in
continuous CR for 8 years and 1 had a 23-monthTable 1. Characteristics of 36 Patients with Primary Systemic Anaplastic Large Cell Lymphoma
Characteristic No. (%)
Age (yrs) Median age 39 (17 - 67)
Gender Male 29 (81)
Female 7 (19)




Primary extranodal lymphoma without lymphadenopathy 6 (17)
Extranodal site of ALCL involvement
Bone 7 (19)




Bone marrow 5 (14)
Liver 5 (14)
Stomach and duodenum 5 (14)




No. extranodal site None 10 (28)
1 11 (30)
2 15 (42)




B symptoms Absent 15 (42)
Present 21 (58)
Serum LDH level 1 × normal 11 (30)
> 1 × normal 25 (70)








ALK-1 Absent 17 (47)
Present 13 (36)
Unknown 6 (17)
ALCL, anaplastic large cell lymphoma; ECOG, the Eastern Cooperative Oncology Group; LDH, lactate
dehydrogenase; IPI, International Prognostic Index; ALK-1, anaplastic lymphoma kinase-1.
Soo Jung Park, et al.
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response whereas the third had a transient
response with 2-month duration from relapse to
death.
Survival
The median follow-up period was 47 months.
OS rate was 57% at 2 years and 45% at 5 years,
while EFS rate was 45% at 2 years and 15% at 5
years (Fig. 1). Median OS and EFS were 49 and
17 months, respectively.
Univariate analysis showed that performance
(p= 0.035), IPI (p = 0.025), and age-adjusted IPI (p
= 0.034) were significantly related to OS (Table 3
Table 2. Comparison of 30 Patients with ALK+ and ALK-- Primary Systemic Anaplastic Large Cell Lymphoma
Characteristic ALK+ (%) ALK-- (%) p value
No. (%) 13 (43) 17 (57)
Median age (yrs)* 33 43 0.047
Gender
Male 11 (85) 13 (76)
Female 2 (15) 4 (24) 0.469
Ann Arbor stage
I-II 2 (15) 7 (41)
III-IV 11 (85) 10 (59) 0.13
Primary extranodal lymphoma 1 (8) 4 (24) 0.355
Extranodal involvement
Absent 3 (23) 4 (24)
Present 10 (77) 13 (76) 0.66
ECOG scale
0 - 1 8 (62) 11 (65)
2 - 4 5 (38) 6 (35) 0.861
B symptoms
Absent 4 (31) 9 (53)
Present 9 (69) 8 (47) 0.20
Serum LDH
1 × normal 5 (38) 6 (35)
> 1 × normal 8 (62) 11 (65) 0.861
IPI score
Low and low-intermediate 8 (62) 11 (65)
High-intermediate and high 5 (38) 6 (35) 0.861
Age-adjusted IPI
Low and low-intermediate 4 (31) 7 (41)
High-intermediate and high 9 (69) 10 (59) 0.421
ECOG, the Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; IPI, International Prognostic Index.
Chi-square test was used to compare with other factors except for age.
*Independent t test was used to compare with other factors except for age.
Primary extranodal lymphoma without any lymph node involvement.Soo Jung Park, et al.
Yonsei Med J Vol. 49, No. 4, 2008
and Fig. 2). The survival rates were 61.5 and 20.0%
in ALK+ and ALK ALCL groups, respectively.
However, OS did not differ significantly between
ALK+ and ALK groups (p = 0.483) (Fig. 3).
Cause of death
Sixteen patients (44%) died during the study
period, 8 from progression of ALCL including
superior vena cava syndrome, venoocclusive
disease proven by autopsy and acute respiratory
distress syndrome (ARDS) due to lung metastasis.
Six patients died of infection and 2 died of
unknown causes. Among the 6 patients who died
of infection, 4 were diagnosed as sepsis or septic
shock with neutropenia, 1, biliary sepsis due to
hepatic infiltration of lymphoma, and the other,
Table 3. Univariate Analysis of Predictive Variables for
Overall Survival
Variable p value
Age (< 60 yrs vs. 60 yrs) 0.866
Gender (male vs. female) 0.616
Ann Arbor stage (1,2 vs. 3,4) 0.260
Primary extranodal lymphoma 0.650
Extranodal involvement (0 vs. 1) 0.151
Performance (0,1 vs. 2,3,4) 0.035
B symptom (positive vs. negative) 0.959
LDH (normal range vs. > normal) 0.071
IPI (low vs. high) 0.025
Age-adjusted IPI (low vs. high) 0.034
ALK (positive vs. negative)* 0.483
LDH, lactate dehydrogenase; IPI, International Prognostic
Index; ALK, anaplastic lymphoma kinase.
*Survival according to ALK in subgroups with 30 patients
was compared using Breslow method.
Other factors except for ALK expression were compared using
log-rank method.
Fig. 1. OS and EFS of 36 patients with primary systemic
ALCL (median 49.0 and 17.0 months; 5-years survival rate
45 and 15%, respectively). OS, overall survival; EFS, event-
free survival.
Fig. 2. OS according to per-
formance and International
Prognostic Index in 36
patients. OS, overall survival;
IPI, International Prognostic
Index.Fig. 3. OS and EFS of 30
patients with ALK+ and ALK--
primary systemic ALCL
(median 17.0 months; 2-year
EFS rate 45%; 5-year EFS rate
15%). OS, overall survival;
EFS, event-free survival; ALK,
anaplastic lymphoma kinase;
ALCL, anaplastic large cell
lymphoma.
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ARDS resulting from pneumonia. The parents or
responsible individuals of some patients agreed to
DNR (Do Not Resuscitate), therefore, some
patients were discharged to the primary hospital
with no hope of recovery.
DISCUSSION
Our retrospective analysis of 11 years' experi-
ence at a single institution contributes to our deeper
understanding of the clinical features, responses
to treatment, survival, and prognosis in adult
patients with primary systemic ALCL in Korea.
We found that the clinical features of adult
patients with primary systemic ALCL in Korea
were similar to those of Western countries in that
ALCL affects mostly young men and frequently
presents with advanced disease. The male/female
ratio (4.1), however, was markedly higher than
those found in Western studies (1.4 - 1.8).
1,13 On
the other hand, the ratio was similar to those
shown at other Korean and Asian institutions.
14,15
Genetic background might be attributed to this
difference, nevertheless, it should be confirmed by
further prospective multi-center studies with
molecular genetic analysis in a larger number of
patients.
The main epidemiologic feature was a relatively
higher incidence in the fourth (28%) and fifth
(28%) decades of life and a median age of 39 years,
a finding in close agreement with previous
reports,
16,17 but in disagreement with other earlier
studies that showed a bimodal age distribution
with a larger peak in the second and third
decades and a smaller peak in the sixth and
seventh decades.
9 However, the distribution of
elderly patients could be underestimated because
elderly patients are generally reluctant to receive
chemotherapy in Korea. For example, 3 patients
over 60 years of age were excluded during enroll-
ment in this study. One patient who died before
receiving any induction therapy was 62 years old,
and 2 whose medical records were insufficient
were 66 and 77 years old, respectively. They
refused to receive any chemotherapy.
In many Western studies, ALK expression has
been shown to correlate with young age, systemic
disease, and good prognosis.
18-21 In our study
period, immunohistochemical staining of ALK
protein was repeated and confirmed prognostic
importance in most available cases (30/36). We
found that ALK patients tended to be older than
ALK+ patients, however, these groups did not
differ in extranodal involvement, advanced
disease, high risk IPI and age-adjusted IPI group
assignments. In addition, we found that these
groups showed no significant differences in OSSoo Jung Park, et al.
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and EFS rate, findings similar to those previously
reported.
17,22 The differences observed between
Korean and Western patients in small descriptive
studies should be handled with care.
Five out of 13 patients with ALK+ ALCL died
within 1 year of diagnosis. Their stages were all
classified as III or IV. Extranodal involvements
were observed in the lung, liver, soft tissue, or
bone marrow. Bone marrow involvement might
have provoked pancytopenia and made patients
vulnerable to sepsis. Biliary sepsis was caused by
hepatic infiltration of lymphoma cells. These
characteristics of the 5 patients who died within
1 year of diagnosis affected the cross line of the
2 survival courses in spite of actual good
prognosis in the AKL+ group.
Primary systemic ALCL often takes an aggres-
sive clinical course for which combination therapy
is warranted. It is not easy to directly compare
response rate to each treatment regimen because
various chemotherapy regimens were applied in
previous studies, and primary cutaneous ALCL
patients who had better prognosis were included
in some studies.
1,13,16,23 In Korea, our CR rate (51%)
of whole chemotherapy regimen was lower than
that (62%) found in previous study that enrolled
only primary systemic ALCL patients.
14 Meanwhile,
the proportion of CHOP-based regimen reached
up to 91% (32/35) of our whole chemotherapy
regimens. The overall response rate of CHOP-
based regimen was 91% with CR in 50% and PR
in 41%. Therefore, our protocol is considerably
homogenous to compare with previous reports,
showing 50%.
14 Moreover, high dose chemotherapy
followed by autologous peripheral blood stem cell
transplantation might be acceptable in relapsed
patients but the small number of cases makes it
difficult to draw a firm conclusion.
The data, which were derived from a small
number of patients enrolled and at a single
tertiary center, might cause a selection bias in this
study. The small number of enrolled patients may
be due to low incidence of adult primary ALCL
in Korea. According to the 2002 Annual Report of
the Korea Central Cancer Registry, only 1.9% of
non-Hodgkin's lymphoma patients have ALCL.
Another limitation was that we could not include
analysis of recently reported common prognostic
factors of primary ALCL (CD56, MUC-1, and
survivin) on 30 patients available. It might be a
good topic for future studies on ALCL.
In summary, we found that advanced disease
and extranodal involvement are frequent, and
confirmed male predominance in Korean adult
primary systemic ALCL patients. OS was 49
months, and CR and PR rates to CHOP-based
chemotherapy were 50 and 41%, respectively.
Univariate analysis showed that performance
status, IPI, and age-adjusted IPI score predicted
OS, but not ALK expression. For further
evaluation of optimal treatment of Korean ALCL
patients, a large national or multi-institutional
prospective study is needed.
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